摘要
目的:评价沙美特罗氟替卡松(salmeterol/fluticasone propionate,SFP)对稳定期慢性阻塞性肺病(chronic obstructivepulmonary diseases,COPD)患者肺功能的影响。方法:计算机检索MEDLINE、EMbase、中国Cochrane中心临床对照试验资料数据库、中国生物医学文献数据库(CBMdisk)和中国中医药科技文献数据库(TCMLRS)中2000年1-12月发表的文献,收集SFP治疗稳定期慢性阻塞性肺疾病患者的临床研究,对符合纳入标准的文献进行质量评价并进行系统评价。结果:符合纳入标准的文献共24篇,其中中文23篇,英文1篇;Jadad评分17篇为1分,6篇为2分,1篇为3分;13项研究的合并分析显示,50/250μg的SFP能增加第一秒用力呼气容积FEV1(L);5项研究的合并分析显示,50/500μg的SFP可增加FEV1(L);10项研究的合并分析显示,50/250μg的SFP不能增加FEV1/用力肺活量FVC(%),WMD(95%CI)为1.93(–3.83,7.69),不具有统计学意义(P=0.51);7项研究的合并分析显示,50/500μg的SFP能增加FEV1/FVC(%);13项研究的合并分析显示,50/250μg的SFP能增加FEV1占预计值百分比;6项研究的合并分析显示,50/500μg的SFP能增加FEV1占预计值百分比。结论:本系统评价结果表明SFP能改善COPD患者的肺功能,但纳入本研究的文献质量欠佳,本文结论有待大规模的随机对照临床试验进一步证实。
OBJECTIVE To evaluate the effect of salmeterol/fluticasone propionate（SFP） on pulmonary function for stable chronic obstructive pulmonary disease systematically.METHODS Included studies retrieved from Medline,EMbase,Chinese Cochrane Library,CBMdisk and TCMLRS（2001.1–12） were evaluated by two reviewers alone and cross-checked.The Meta-analyses of studies were conducted using RevMan 4.3 software.RESULTS Twenty four studies met the inclusion criteria（23 Chinese and 1 English）.The Jadad score was 1 for 17 studies,2 for 6 studies and 3 for 1 study.The pooled results of 13 studies showed that 50/250 μg of SFP could increase the first second forced expiratory volume（FEV1）;Five studies demonstrated that 50/500 μg of SFP could also increase FEV1;The pooled analysis of 10 studies showed that 50/250 μg of SFP could not improve FEV1/FVC rate as compared with control group;However,seven studies found 50/500 μg of SFP could increase FEV1/FVC ratio;13 studies showed 50/250 μg of SFP could increase the percentage of FEV1 percentage in predicted value,and six studies found 50/500 μg of SFP had the same efficacy.CONCLUSION The evidence is suggested that salmeterol/fluticasone may improve pulmonary function in patients with chronic obstructive pulmonary disease.However,owing to limited data and high risk of bias of the included studies,further rigorously controlled trials are required.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2012年第18期1463-1467,共5页
Chinese Journal of Hospital Pharmacy
基金
上海市医院药学科研基金-呼吸专项-沙美特罗替卡松治疗慢性阻塞性肺病的系统评价(编号:2010-YY-04-04)
关键词
沙美特罗氟替卡松
慢性阻塞性肺病
系统评价
salmeterol/fluticasone propionate； chronic obstructive pulmonary diseases； systematic review；
